Vaccinex. has been granted a patent for methods to inhibit tumor growth in Plexin-B1-expressing cancers. The approach involves administering an isolated binding molecule targeting semaphorin-4D (SEMA4D) alongside immune-modulating therapies, including anti-LAG-3 antibodies, to enhance therapeutic efficacy. GlobalData’s report on Vaccinex gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vaccinex, Personalized cancer vaccines was a key innovation area identified from patents. Vaccinex's grant share as of July 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Cancer treatment using sema4d-targeting antibodies and immune therapy
The granted patent US12070500B2 outlines a method for inhibiting tumor growth in cancer patients through the administration of a combination of specific antibodies. The primary components of this method include an isolated antibody or its antigen-binding fragment that targets semaphorin-4D (SEMA4D) and an anti-Lymphocyte Activation Gene 3 (LAG-3) antibody. The claims specify that the SEMA4D-targeting antibody comprises defined variable heavy and light chains, with specific sequences provided (SEQ ID NO: 6-8 for heavy chain and SEQ ID NO: 14-16 for light chain). The method is designed to enhance therapeutic efficacy compared to administering either antibody alone, and it may also include additional antibodies that inhibit immune checkpoint blockade, such as anti-PD-1 antibodies.
The patent further details that the SEMA4D-targeting antibody can inhibit the interaction between SEMA4D and its receptor, Plexin-B1, and disrupt SEMA4D-mediated signaling. The method is applicable to a wide range of cancers, including various carcinomas, lymphomas, and sarcomas, among others. The claims also emphasize the potential for increased levels of interferon-gamma (IFN?) in the tumor environment when using the combination therapy. Overall, the patent presents a multi-faceted approach to cancer treatment that leverages the synergistic effects of targeting multiple immune pathways to improve patient outcomes.
To know more about GlobalData’s detailed insights on Vaccinex, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
